CLINICAL TRIALS PROFILE FOR VASOPRESSIN

All Clinical Trials for VASOPRESSIN

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00004360 ↗	Study of Genotype and Phenotype Expression in Congenital Nephrogenic Diabetes Insipidus	Completed	Northwestern University		1995-09-01	OBJECTIVES: I. Determine the relationship between genotype variations and clinical phenotype in patients with congenital nephrogenic diabetes insipidus.
NCT00004360 ↗	Study of Genotype and Phenotype Expression in Congenital Nephrogenic Diabetes Insipidus	Completed	National Center for Research Resources (NCRR)		1995-09-01	OBJECTIVES: I. Determine the relationship between genotype variations and clinical phenotype in patients with congenital nephrogenic diabetes insipidus.
NCT00004363 ↗	Study of the Pathogenesis and Pathophysiology of Familial Neurohypophyseal Diabetes Insipidus	Completed	Northwestern University		1995-12-01	OBJECTIVES: I. Determine whether diverse mutations of the vasopressin-neurophysin II (AVP-NPII) gene cause autosomal dominant familial neurohypophyseal diabetes insipidus by directing the production of an abnormal preprohormone. II. Determine whether the AVP-NPII gene-directed preprohormone accumulates and destroys magnocellular neurons because it cannot be folded and processed efficiently.
NCT00004363 ↗	Study of the Pathogenesis and Pathophysiology of Familial Neurohypophyseal Diabetes Insipidus	Completed	National Center for Research Resources (NCRR)		1995-12-01	OBJECTIVES: I. Determine whether diverse mutations of the vasopressin-neurophysin II (AVP-NPII) gene cause autosomal dominant familial neurohypophyseal diabetes insipidus by directing the production of an abnormal preprohormone. II. Determine whether the AVP-NPII gene-directed preprohormone accumulates and destroys magnocellular neurons because it cannot be folded and processed efficiently.
NCT00004364 ↗	Study of Novel Types of Familial Diabetes Insipidus	Unknown status	Northwestern University		1995-12-01	OBJECTIVES: I. Define the phenotype and genotype of previously unrecognized types of familial diabetes insipidus (FDI) in kindreds with atypical or novel forms of FDI.
NCT00004364 ↗	Study of Novel Types of Familial Diabetes Insipidus	Unknown status	National Center for Research Resources (NCRR)		1995-12-01	OBJECTIVES: I. Define the phenotype and genotype of previously unrecognized types of familial diabetes insipidus (FDI) in kindreds with atypical or novel forms of FDI.

Clinical Trial Conditions for VASOPRESSIN

Condition Name

Condition Name for VASOPRESSIN
Intervention	Trials
Septic Shock	24
Hyponatremia	13
Healthy	11
Congestive Heart Failure	9

Condition MeSH

Condition MeSH for VASOPRESSIN
Intervention	Trials
Shock	36
Shock, Septic	28
Heart Failure	22
Hemorrhage	18

Clinical Trial Locations for VASOPRESSIN

Trials by Country

Trials by Country for VASOPRESSIN
Location	Trials
United States	320
Canada	28
Germany	22
Italy	17
Greece	15

Trials by US State

Trials by US State for VASOPRESSIN
Location	Trials
California	21
New York	19
Texas	17
Ohio	16
Illinois	14

Clinical Trial Progress for VASOPRESSIN

Clinical Trial Phase

Clinical Trial Phase for VASOPRESSIN
Clinical Trial Phase	Trials
Phase 4	50
Phase 3	34
Phase 2/Phase 3	17

Clinical Trial Status

Clinical Trial Status for VASOPRESSIN
Clinical Trial Phase	Trials
Completed	135
Recruiting	37
Unknown status	27

Clinical Trial Sponsors for VASOPRESSIN

Sponsor Name

Sponsor Name for VASOPRESSIN
Sponsor	Trials
Vantia Ltd	8
Otsuka Pharmaceutical Co., Ltd.	7
National Institute of Mental Health (NIMH)	7

Sponsor Type

Sponsor Type for VASOPRESSIN
Sponsor	Trials
Other	311
Industry	71
NIH	16